Amendments to the Claims:

Listing of Claims:

Claim 1 (original): A compound of formula I



(I),

wherein

m is from 1 to 5;

R_1 is lower alkyl-sulfonyl; unsubstituted, mono- or di-substituted amino-sulfonyl; unsubstituted, mono- or di-substituted amino; a heterocyclic radical; lower alkyl substituted by amino, mono- or di-lower alkyl substituted amino, a heterocyclic radical, heterocyclyl-NH- or heterocyclyl-O- wherein heterocyclyl is bound to NH or O via a carbon ring atom; a radical R_4-lower alkyl-X-, wherein R_4 is hydrogen, halogen, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical, and X is -S- or -O-; or a radical R_5-C(=O)-, wherein R_5 is hydrogen, unsubstituted or substituted lower alkyl, free or etherified hydroxy, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical; wherein the R_1 substituents are selected independently of one another if m>1;

or two vicinal R_1 substituents together with the phenyl carbon atoms to which they are attached form a heterocyclic ring;

R_2 is hydrogen, unsubstituted or substituted lower alkyl or a heterocyclic radical; and

Z is benzyloxy;

or a salt of the said compounds, with the proviso that the compound {4-[3-(4-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(2-dimethylamino-ethoxy)-phenyl]-amine is excluded.

Claim 2 (original): A compound of claim 1 of formula Ib



(Ib),

wherein

m is from 1 to 5;

R_1 is lower alkyl-sulfonyl; unsubstituted, mono- or di-substituted amino-sulfonyl; unsubstituted, mono- or di-substituted amino; a heterocyclic radical; lower alkyl substituted by amino, mono- or di-lower alkyl substituted amino, a heterocyclic radical, heterocyclyl-NH- or heterocyclyl-O- wherein heterocyclyl is bound to NH or O via a carbon ring atom; a radical R_4-lower alkyl-X-, wherein R_4 is hydrogen, halogen, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical, and X is -S- or -O-; or a radical R_5-C(=O)-, wherein R_5 is hydrogen, unsubstituted or substituted lower alkyl, free or etherified hydroxy, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical; wherein the R_1 substituents are selected independently of one another if m>1;

or two vicinal R_1 substituents together with the phenyl carbon atoms to which they are attached form a heterocyclic ring;

R_2 is hydrogen, unsubstituted or substituted lower alkyl or a heterocyclic radical; and

Z is benzyloxy;

or a salt of the said compounds, with the proviso that the compound {4-[3-(4-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(2-dimethylamino-ethoxy)-phenyl]-amine is excluded.

Claim 3 (currently amended): A compound according to ~~claims 1 or 2~~claim 1, in which R1 is a heterocyclic radical; lower alkyl substituted by mono- or di-lower alkyl substituted amino, a heterocyclic radical, heterocyclyl-NH- or heterocyclyl-O- wherein heterocyclyl is bound to NH

or O via a carbon ring atom; a radical R_4-lower alkyl-X-, wherein R_4 is mono- or di-substituted amino, or a heterocyclic radical, and X is -S- or -O-; or a radical R_5-C(=O)-, wherein R_5 is unsubstituted, mono- or di-substituted amino, or a heterocyclic radical; m is 1;
R2 is hydrogen;
or a or a salt of the said compounds, with the proviso that the compound {4-[3-(4-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(2-dimethylamino-ethoxy)-phenyl]-amine is excluded.

Claim 4 (currently amended): A compound according to ~~claims 1, 2 or 3~~claim 1, in which R1is is a lower alkyl substituted by a di-lower alkyl substituted amino, an alkyl substituted 5- or 6- membered heterocyclyl -NH-, heterocyclyl-NH- wherein heterocyclyl is bound to NH via a carbon ring atom; a radical R_4-lower alkyl-O-, wherein R_4 is di-substituted amino; or a radical R_5-C(=O)-, wherein R_5 is unsubstituted, mono- or di-substituted amino, or a heterocyclic radical; m is 1;
R2 is hydrogen;
or a or a salt of the said compounds, with the proviso that the compound {4-[3-(4-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(2-dimethylamino-ethoxy)-phenyl]-amine is excluded.

Claim 5 (currently amended): A compound according to ~~claims 1, 2, 3 or 4~~claim 1, in which R_1 is a lower alkyl substituted by a di-lower alkyl substituted amino, or a C_1-C_4 alkyl-substituted piperazinyl, or a pyrrolidinyl; piperidinyl wherein piperidinyl is bound to NH via a carbon ring atom; a radical R_4- lower alkyl-O-, wherein R_4 is amino di-substituted by lower alkyl; or R_5-C(=O)-, wherein R_5 is a C_1-C_4 alkyl-substituted piperazinyl;
m is 1;
R2 is hydrogen;
or a or a salt of the said compounds, with the proviso that the compound {4-[3-(4-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(2-dimethylamino-ethoxy)-phenyl]-amine is excluded.

Claim 6 (original): A compound chosen from the group consisting of;
{4-[3-(3-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(4-pyrrolidin-1-ylmethyl-phenyl)-amine;
{4-[3-(3-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(4-dimethyl aminomethyl-phenyl)-amine;

(4-{4-[3-(3-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-ylamino}-phenyl)-(4-methyl-piperazin-1-yl)-methanone;
{4-[3-(3-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-amine;and
4-{4-[3-(3-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-ylamino}-N-(2,2,6,6-tetramethyl-piperidin-4-yl)-benzamide.

Claim 7 (original): A compound of claim 2 wherein R_1 is lower alkyl substituted by amino, lower alkyl substituted by a heterocyclic radical or R_5-C(O)-.

Claim 8 (original): A compound of claim 7 wherein R_1 is lower alkyl substituted by amino.

Claim 9 (original): A compound of claim 7 wherein R_1 is lower alkyl substituted by a heterocyclic radical.

Claim 10 (original): A compound of claim 9 wherein the alkyl portion is methylene and the heterocyclic radical is a five or six membered ring containing one or two nitrogens and is unsubstituted or substituted on one or more carbon atoms by a lower alkyl group.

Claim 11 (original): A compound of claim 7 wherein R_1 is R_5-C(O)-.

Claim 12 (original): A compound of claim 11 wherein R_5 is substituted amino or a heterocyclic radical, wherein the heterocyclic radical is a five or six membered ring containing one or two nitrogens and is unsubstituted or substituted on one or more carbon atoms by a lower alkyl group.

Claim 13 (currently amended): A compound of ~~any one of claims 7-12~~claim 7 wherein R_2 is H.

Claim 14 (currently amended): A compound of ~~any one of claims 7-13~~claim 7 wherein m is 1.

Claim 15 (original): A compound according to formula I



(I),

wherein

m is from 1 to 5;

R_1 is lower alkyl-sulfonyl; unsubstituted, mono- or di-substituted amino-sulfonyl; unsubstituted, mono- or di-substituted amino; a heterocyclic radical; lower alkyl substituted by amino, mono- or di-lower alkyl substituted amino, a heterocyclic radical, heterocyclyl-NH- or heterocyclyl-O- wherein heterocyclyl is bound to NH or O via a carbon ring atom; a radical R_4-lower alkyl-X-, wherein R_4 is hydrogen, halogen, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical, and X is -S- or -O-; or a radical R_5-C(=O)-, wherein R_5 is hydrogen, unsubstituted or substituted lower alkyl, free or etherified hydroxy, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical; wherein the R_1 substituents are selected independently of one another if m>1;

or two vicinal R_1 substituents together with the phenyl carbon atoms to which they are attached form a heterocyclic ring;

R_2 is hydrogen, unsubstituted or substituted lower alkyl or a heterocyclic radical; and

Z is benzyloxy;

or a salt of the said compounds, for medical use.

Claim 16-17 (canceled)

Claim 18 (currently amended): ~~Use~~ A method according to claim ~~17~~20, in which the disease is chosen form the group consisting of;

tumours, for example breast, renal, prostate, colorectal, thyroid, ovarian, pancreas, neuronal, lung, uterine and gastro-intestinal tumours as well as osteosarcomas and melanomas.

Claim 19 (currently amended): ~~Use of a compound according to claims 1-14 or 15 for the manufacture of a medicament to be used in the treatment of~~A method according to claim 20 wherein the disease is a graft vessel disease, or for preventing or treating vein graft stenosis, restenosis and/or vascular occlusion following vascular injury.

Claim 20 (original): A method of treating a disease which responds to inhibition of IGF-1R in a mammal, which comprises administering to the mammal an effective IGF-1R inhibiting amount of a compound of formula Ia



(Ia),

wherein

m is from 1 to 5;

R_1 is lower alkyl-sulfonyl; unsubstituted, mono- or di-substituted amino-sulfonyl; unsubstituted, mono- or di-substituted amino; a heterocyclic radical; lower alkyl substituted by amino, mono- or di-lower alkyl substituted amino, a heterocyclic radical, heterocyclyl-NH- or heterocyclyl-O- wherein heterocyclyl is bound to NH or O via a carbon ring atom; a radical R_4-lower alkyl-X-, wherein R_4 is hydrogen, halogen, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical, and X is -S- or -O-; or a radical R_5-C(=O)-, wherein R_5 is hydrogen, unsubstituted or substituted lower alkyl, free or etherified hydroxy, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical; wherein the R_1 substituents are selected independently of one another if m>1;

or two vicinal R_1 substituents together with the phenyl carbon atoms to which they are attached form a heterocyclic ring;

R_2 is hydrogen, unsubstituted or substituted lower alkyl or a heterocyclic radical; and

Z is benzyloxy;

or a pharmaceutically acceptable salt thereof.

Claim 21 (original): A method of claim 20, which comprises administering to the mammal an effective IGF-1R inhibiting amount of a compound of formula Ib



(Ib),

wherein

m is from 1 to 5;

R_1 is lower alkyl-sulfonyl; unsubstituted, mono- or di-substituted amino-sulfonyl; unsubstituted, mono- or di-substituted amino; a heterocyclic radical; lower alkyl substituted by amino, mono- or di-lower alkyl substituted amino, a heterocyclic radical, heterocyclyl-NH- or heterocyclyl-O- wherein heterocyclyl is bound to NH or O via a carbon ring atom; a radical R_4-lower alkyl-X-, wherein R_4 is hydrogen, halogen, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical, and X is a -S- or -O-; or a radical R_5-C(=O)-, wherein R_5 is hydrogen, unsubstituted or substituted lower alkyl, free or etherified hydroxy, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical; wherein the R_1 substituents are selected independently of one another if m>1;

or two vicinal R_1 substituents together with the phenyl carbon atoms to which they are attached form a heterocyclic ring;

R_2 is hydrogen, unsubstituted or substituted lower alkyl or a heterocyclic radical; and

Z is benzyloxy;

or a pharmaceutically acceptable salt thereof.

Claim 22 (canceled)

Claim 23 (currently amended): A pharmaceutical composition which comprises a pharmaceutically effective amount of a compound of ~~any one of claims 1-14 or 15~~claim 1 and a pharmaceutically acceptable carrier.

Claim 24 (currently amended): A pharmaceutical composition which comprises a pharmaceutically effective amount of a compound of ~~any one of claims 1-14 or 15~~claim 1, together with inhibitors of the enzymes of polyamine synthesis, inhibitors of protein kinase C, inhibitors of other tyrosine kinases, cytokines, negative growth regulators, for example TGF-β or IFN-β, aromatase inhibitors, antioestrogens and/or cytostatic drugs; and a pharmaceutically acceptable carrier.

Claim 25 (new): A pharmaceutical composition which comprises a pharmaceutically effective amount of a compound of claim 15 and a pharmaceutically acceptable carrier.

Claim 26 (new): A pharmaceutical composition which comprises a pharmaceutically effective amount of a compound of claim 15, together with inhibitors of the enzymes of polyamine synthesis, inhibitors of protein kinase C, inhibitors of other tyrosine kinases, cytokines, negative growth regulators, for example TGF-β or IFN-β, aromatase inhibitors, antioestrogens and/or cytostatic drugs; and a pharmaceutically acceptable carrier.